TMO

$685.581.64%-11.42

Thermo Fisher Scientific Inc (TMO)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$697.00

Aprire:

$692.44

Volume 24 ore:

784,680

Volume relativo:

0.32

Capitalizzazione di mercato:

$253.49B

Reddito:

$45.20B

Utile/perdita netta:

$6.87B

Rapporto P/E:

37.69

EPS:

$18.19

Flusso di cassa netto:

$6.75B

1W Prestazione:

+0.10%

1M Prestazione:

+4.70%

6M Prestazione:

+46.11%

1Y Prestazione:

+20.83%

Intervallo 1D:

$679.40$693.76

Intervallo di 1 settimana:

$676.00$711.85

Portata 52W:

$435.27$711.85

Profilo aziendale di Thermo Fisher Scientific Inc (TMO)

Nome

Thermo Fisher Scientific Inc

Settore

Healthcare

Industria

Diagnostics & Research

Telefono

(781) 622-1000

Indirizzo

168 THIRD AVENUE, WALTHAM, MA, USA

Dipendente

125,000

@thermofisher

Prossima data di guadagno

null

Ultimi documenti SEC

SEC

Discussioni di TMO su X

Confronta TMO con DHR, NTRA, IDXX, A

Azioni	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TMO Thermo Fisher Scientific Inc	$253.49B	$47.35B	$7.07B	$6.75B	$18.19
DHR Danaher Corp	$161.55B	$25.61B	$4.33B	$5.29B	$5.17
NTRA Natera Inc	$55.97B	$2.71B	-$192.35M	$71.51M	-$1.64
IDXX Idexx Laboratories Inc	$52.54B	$4.55B	$1.14B	$1.06B	$13.59
A Agilent Technologies Inc	$48.84B	$7.37B	$1.44B	$1.09B	$4.98

Thermo Fisher Scientific Inc Azioni (TMO) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-09-09	Aggiornamento	UBS	Neutral → Buy
2026-09-03	Iniziato	CLSA	Outperform
2026-06-26	Resumed	Bernstein	Mkt Perform
2026-06-11	Iniziato	Piper Sandler	Neutral
2026-06-03	Downgrade	HSBC Securities	Buy → Hold
2026-06-02	Resumed	Wolfe Research	Outperform
2026-05-15	Resumed	RBC Capital Mkts	Sector Perform
2026-03-27	Iniziato	DZ Bank	Buy
2025-12-11	Aggiornamento	Citigroup	Neutral → Buy
2025-12-09	Iniziato	Goldman	Buy
2025-12-08	Aggiornamento	KeyBanc Capital Markets	Sector Weight → Overweight
2025-12-02	Resumed	Morgan Stanley	Overweight
2025-12-01	Aggiornamento	HSBC Securities	Hold → Buy
2025-09-11	Aggiornamento	Barclays	Equal Weight → Overweight
2025-08-19	Iniziato	William Blair	Outperform
2025-07-24	Downgrade	HSBC Securities	Buy → Hold
2025-07-11	Aggiornamento	Scotiabank	Sector Perform → Sector Outperform
2025-07-09	Downgrade	UBS	Buy → Neutral
2025-01-10	Aggiornamento	Bernstein	Mkt Perform → Outperform
2024-12-23	Iniziato	Scotiabank	Sector Perform
2024-10-14	Iniziato	Redburn Atlantic	Buy
2024-10-01	Iniziato	Stephens	Overweight
2024-08-28	Iniziato	Wells Fargo	Overweight
2024-06-03	Resumed	Jefferies	Buy
2024-03-18	Resumed	Citigroup	Neutral
2024-01-24	Downgrade	Barclays	Overweight → Equal Weight
2024-01-08	Downgrade	Bernstein	Outperform → Mkt Perform
2023-12-18	Iniziato	HSBC Securities	Buy
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-10-26	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
2023-10-25	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2023-09-28	Iniziato	Bernstein	Outperform
2023-09-06	Resumed	Citigroup	Buy
2023-07-19	Iniziato	Raymond James	Outperform
2023-07-19	Reiterato	Robert W. Baird	Outperform
2023-07-13	Aggiornamento	Credit Suisse	Neutral → Outperform
2023-04-04	Reiterato	Barclays	Overweight
2022-12-14	Iniziato	Deutsche Bank	Buy
2022-12-07	Iniziato	RBC Capital Mkts	Outperform
2022-10-27	Downgrade	The Benchmark Company	Buy → Hold
2022-08-25	Iniziato	Credit Suisse	Neutral
2022-04-25	Downgrade	Wells Fargo	Equal Weight → Underweight
2022-01-26	Resumed	Barclays	Overweight
2021-10-20	Aggiornamento	Citigroup	Neutral → Buy
2021-10-15	Resumed	Cowen	Outperform
2021-08-05	Resumed	Credit Suisse	Outperform
2021-07-16	Iniziato	The Benchmark Company	Buy
2021-03-18	Aggiornamento	KeyBanc Capital Markets	Sector Weight → Overweight
2021-03-03	Iniziato	Barclays	Overweight
2021-01-08	Aggiornamento	Credit Suisse	Neutral → Outperform
2020-12-16	Downgrade	Citigroup	Buy → Neutral
2020-12-02	Iniziato	Goldman	Buy
2020-11-10	Iniziato	KeyBanc Capital Markets	Sector Weight
2020-09-30	Iniziato	Atlantic Equities	Overweight
2020-09-14	Iniziato	Morgan Stanley	Overweight
2020-08-20	Resumed	JP Morgan	Overweight
2020-07-15	Aggiornamento	Cleveland Research	Neutral → Buy
2020-07-07	Reiterato	Needham	Buy
2020-04-23	Reiterato	Needham	Buy
2020-01-31	Reiterato	Needham	Buy
2020-01-22	Iniziato	Credit Suisse	Neutral
2020-01-08	Iniziato	Wells Fargo	Equal Weight
2020-01-07	Iniziato	Citigroup	Buy
2019-11-15	Iniziato	Stifel	Buy
2019-07-25	Reiterato	Needham	Buy
2019-07-16	Downgrade	Needham	Strong Buy → Buy
2019-05-30	Iniziato	Wolfe Research	Outperform
2019-05-23	Reiterato	Needham	Strong Buy
2019-04-22	Reiterato	Needham	Strong Buy
2019-04-16	Reiterato	BofA/Merrill	Buy

Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	44,556.00	42,879.00	42,857.00	44,915.00	39,211.00
Research and development USD (M)	1,397.00	1,390.00	1,337.00	1,471.00	1,406.00
Operating expenses USD (M)	36,810.00	35,542.00	35,998.00	36,522.00	29,183.00
Operating income USD (M)	7,746.00	7,337.00	6,859.00	8,393.00	10,028.00
Income before tax USD (M)	7,308.00	7,037.00	6,298.00	7,835.00	8,841.00
Income tax expense USD (M)	547.00	657.00	284.00	703.00	1,109.00
Net income USD (M)	6,721.00	6,338.00	5,955.00	6,960.00	7,728.00
Basic EPS USD/shares	17.77	16.58	15.52	17.75	19.62
Diluted EPS USD/shares	17.74	16.53	15.45	17.63	19.46
Basic weighted shares shares (M)	377.00	382.00	386.00	392.00	394.00
Diluted weighted shares shares (M)	378.00	383.00	388.00	394.00	397.00
Selling, general and administrative USD (M)	8,732.00	8,595.00	8,445.00	8,993.00	8,007.00

Thermo Fisher Scientific Inc Azioni (TMO) insider trading

Britt Lisa P.Oct 28 '26
Officer
Transazione
Proposed Sale
Costo
$706.45
#Azioni
2,831
Valore ($)
1,999,960
#Azioni Totale
0
Pettiti GianlucaAug 31 '26
Officer
Transazione
Proposed Sale
Costo
$614.38
#Azioni
4,133
Valore ($)
2,539,233
#Azioni Totale
0
Pettiti GianlucaAug 31 '26
President & COO
Transazione
Sale
Costo
$614.38
#Azioni
4,133
Valore ($)
2,539,233
#Azioni Totale
23,216
Pettiti GianlucaAug 31 '26
President & COO
Transazione
Option Exercise
Costo
$309.63
#Azioni
3,733
Valore ($)
1,155,849
#Azioni Totale
26,949
CASPER MARC NAug 24 '26
Chairman & CEO
Transazione
Sale
Costo
$627.05
#Azioni
275
Valore ($)
172,439
#Azioni Totale
123,925
CASPER MARC NAug 24 '26
Officer
Transazione
Proposed Sale
Costo
$627.05
#Azioni
275
Valore ($)
172,438
#Azioni Totale
0
CASPER MARC NAug 24 '26
Chairman & CEO
Transazione
Option Exercise
Costo
$309.63
#Azioni
275
Valore ($)
85,148
#Azioni Totale
124,200
CASPER MARC NAug 21 '26
Chairman & CEO
Transazione
Sale
Costo
$626.92
#Azioni
10,000
Valore ($)
6,269,153
#Azioni Totale
123,925
CASPER MARC NAug 21 '26
Officer
Transazione
Proposed Sale
Costo
$626.91
#Azioni
10,000
Valore ($)
6,269,123
#Azioni Totale
0
CASPER MARC NAug 20 '26
Chairman & CEO
Transazione
Option Exercise
Costo
$309.63
#Azioni
10,000
Valore ($)
3,096,300
#Azioni Totale
133,925

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Britt Lisa P.	Officer	Oct 28 '26	Proposed Sale	$706.45	2,831	1,999,960	0
Pettiti Gianluca	Officer	Aug 31 '26	Proposed Sale	$614.38	4,133	2,539,233	0
Pettiti Gianluca	President & COO	Aug 31 '26	Sale	$614.38	4,133	2,539,233	23,216
Pettiti Gianluca	President & COO	Aug 31 '26	Option Exercise	$309.63	3,733	1,155,849	26,949
CASPER MARC N	Chairman & CEO	Aug 24 '26	Sale	$627.05	275	172,439	123,925
CASPER MARC N	Officer	Aug 24 '26	Proposed Sale	$627.05	275	172,438	0
CASPER MARC N	Chairman & CEO	Aug 24 '26	Option Exercise	$309.63	275	85,148	124,200
CASPER MARC N	Chairman & CEO	Aug 21 '26	Sale	$626.92	10,000	6,269,153	123,925
CASPER MARC N	Officer	Aug 21 '26	Proposed Sale	$626.91	10,000	6,269,123	0
CASPER MARC N	Chairman & CEO	Aug 20 '26	Option Exercise	$309.63	10,000	3,096,300	133,925

Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie

06:34 AM

Beat the Market Like Zacks: Marathon Petroleum, Amgen, Chevron in Focus - Zacks Investment Research

06:34 AM

Oct 30, 2026

RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs - Zacks Investment Research

Oct 30, 2026

Oct 28, 2026

Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends, and Forecast - 2026 to 2036 | Precision Medicine Drives 12.7% CAGR and a $305.21 Million Opportunity - GlobeNewswire Inc.

Oct 28, 2026

Oct 27, 2026

15-year-old Designs Low-Cost Device to Monitor Airborne Bacteria in the Environment; Wins $25,000 Top Award at the 2026 Thermo Fisher Scientific Junior Innovators Challenge - GlobeNewswire Inc.

Oct 27, 2026

Top Research Reports for Alphabet, ExxonMobil & Toyota Motor - Zacks Investment Research

Oct 27, 2026

Oct 26, 2026

Thermo Fisher Scientific Inc. stock rises Monday, outperforms market - MarketWatch

Oct 26, 2026

Oct 25, 2026